TriangleAvasopasem (NCT07137871)
Avasopasem trial for Metastatic Hormone Receptor-Positive Breast Cancer (NCT07137871). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for adults with metastatic hormone receptor positive breast cancer that has progressed on a CDK4/6 inhibitor and hormonal therapy.
The idea: add avasopasem to the CDK4/6 inhibitor and hormonal therapy patients are already taking. The study looks at the safety of the combination and whether adding avasopasem improves how well the treatment works.
This phase 1 study plans 35 patients. At UT Health San Antonio, Kate Lathrop leads it.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.